LMR Partners’s Immunome IMNM Stock Holding History

LMR Partners’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.22M	Buy	101,401 +1,401	+1%	+$31.2K	﹤0.01%	833
2025 Q4	$2.15M	Buy	+100,000	New	+$1.76M	﹤0.01%	793

Other funds holding IMNM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

LMR Partners's IMNM Position: Q1 2026 in Review

LMR Partners increased its Immunome (IMNM) stake by 1.4% in Q1 2026, buying an estimated $31.2K and bringing the position to 101,401 shares worth $2.22M. The position accounts for ﹤0.01% of the portfolio, ranked #833.

LMR Partners first reported a position in IMNM in Q4 2025 and has held it in 2 quarters since. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

LMR Partners held 101,401 shares of Immunome worth $2.22M as of Q1 2026.
LMR Partners bought 1,401 Immunome shares in Q1 2026, an estimated $31.2K.
Immunome made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #833 holding.
LMR Partners first reported a position in Immunome in Q4 2025 and has held it in 2 quarters since.
200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.